Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (438)	6/20/2002 1:42:49 PM
From: Jibacoa	Read Replies (1) \| Respond to of 544

GNLB Had a good up-gap today after it announced that European regulators would allow the company to apply for approval of its treatment for lupus through a centralized marketing application that could allow the drug to be approved throughout the European Union.(An FDA decision on approval of Aslera is expected by the end of August).(The FDA originally rejected the S.L.E. drug in June 2001) GNLB stock seems that it may test its May and even its January Hs.<g> siliconinvestor.com siliconinvestor.com Bernard